Chiltern buys Theorem to compete with CRO heavyweights

Two mid-size CROs are slated to merge and contend with the industry's titans, as Chiltern is buying Theorem Clinical Research in a move to strengthen its global presence.

Patheon signs up to manufacture Flexion's lead drug

Contract drugmaker Patheon inked a deal to manufacture Flexion Therapeutics' top prospect as it moves through clinical development.

Quintiles' $950M IPO keeps on giving for PE backers

Two years after Quintiles' trend-setting IPO, the CRO's private equity owners are still profiting from the company's continued growth, pocketing $545 million in a secondary offering.

Icon gets in on the ground floor with a Novartis-backed biotech upstart

Irish CRO Icon has signed on to be the exclusive service provider for a new U.K. biotech startup, planning to help the nascent company advance a trio of Novartis-developed drugs.

AMRI swings to a profit as it slogs through a turnaround

AMRI, rebuilding its business after a string of slow quarters, posted a profit for the first time in 12 months as it looks to hit its stride as a growing contract drug developer.

Parexel returns to growth after a shaky quarter

Parexel International, slashing jobs after a rough run, posted some modest revenue gains in its fiscal fourth quarter, and now the CRO is looking to build some momentum with a jump in new business.

INC raises its 2015 expectations after another strong quarter

CRO INC Research posted another quarter of double-digit revenue growth, lifting its 2015 guidance for the second time to account for a jump in new business.

Patheon unloads some assets on the way to an IPO

Contract drugmaker Patheon is getting out of agrochemicals and selling off a manufacturing plant, narrowing its focus on pharmaceutical development as it plots an IPO.

Covance names a new CEO as it adjusts to life with LabCorp

Covance, acquired by LabCorp for about $6 billion earlier this year, has picked former head of R&D Deborah Keller to take the reins as CEO Joseph Herring retires.

Charles River's revenue slips on slumping R&D demand

Charles River Laboratories saw its sales dip in the second quarter, but the early-stage specialist is counting on some recent acquisitions to spur growth for the full year.

PRA boosts its profit forecast after a strong sales quarter

PRA Health Sciences is ticking up its full-year expectations after another quarter of revenue growth, counting on a steady stream of new business.

Icon dials back its guidance after posting modest sales growth

Icon is again reducing its revenue expectations for 2015 but increasing its profit guidance, counting on a big quarter of business wins to balance some sluggish backlog conversion.

Quintiles restores its rosy outlook after a big quarter

Quintiles is going back to its earlier optimism for 2015, scaling up its previously reduced growth projections after posting a strong sales quarter.

Avista buys another pharma contracting biz

Contract drug developer Avista Pharma Solutions bought the manufacturing, development and animal health services business of rival Scynexis, building up its capacity to take a larger share of an expanding market.

Covance and LabCorp open a new R&D center to pool their expertise

Covance, recently acquired by testing giant LabCorp, has opened a new, expanded clinical research unit in Texas, pairing space for trials alongside a planned patient-service center operated by its parent company.

PRA doubles down on the hunt for new R&D talent

PRA Health Sciences, looking to find the next generation of clinical researchers, is dialing up its recruitment pitch in hopes of meeting the escalating demand for CRO-run trials around the world.

Huntingdon and Harlan raise up to $125M to fund their future together

The recently merged Huntingdon Life Sciences and Harlan Laboratories have convinced their investors to commit up to $125 million in equity financing, lining up the cash they'll need to move forward as a joint entity.

Biocon might spin out its CRO after taking it public

Indian drugmaker Biocon is on the road to taking its in-house CRO public, and the company's founder said she's considering making the company an entirely independent operation.

AMRI bets $174M on manufacturing with latest buyout

Contract drugmaker AMRI paid $174 million for a Spanish manufacturing operation, part of the company's long-term plan to dial up its focus on production.

Almac settles into Singapore with eyes on Asian expansion

Contract drug developer Almac has opened a new shop in Singapore, a facility that will serve as the company's Asian headquarters as it plots more investments in the region.